cyclacillin has been researched along with cefmetazole in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brandsch, M; Luckner, P | 1 |
| Biegel, A; Brandsch, M; Gebauer, S; Hartrodt, B; Neubert, K; Thondorf, I | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Aldini, G; De Luca, L; Marconi, C; Pedretti, A; Regazzoni, L; Vistoli, G | 1 |
4 other study(ies) available for cyclacillin and cefmetazole
| Article | Year |
|---|---|
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Binding Sites; Caco-2 Cells; Dose-Response Relationship, Drug; Humans; Peptide Transporter 1; Protein Binding; Rats; Symporters | 2005 |
Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
Topics: Animals; beta-Lactams; Cell Line, Tumor; Dipeptides; Drug Design; Humans; Mammals; Models, Molecular; Oligopeptides; Peptide Transporter 1; Quantitative Structure-Activity Relationship; Substrate Specificity; Symporters | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping.
Topics: Binding Sites; Computer Simulation; Drug Design; Humans; Ligands; Models, Molecular; Peptides; Protein Binding; Structural Homology, Protein; Symporters | 2011 |